Rationale and design of the Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography IMaging (PARADIGM) registry: A comprehensive exploration of plaque progression and its impact on clinical outcomes from a multicenter serial coronary computed tomographic angiography study

Abstract

BACKGROUND:The natural history of coronary artery disease (CAD) in patients with

Differential association between the progression of coronary artery calcium score and coronary plaque volume progression according to statins: the Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging (PARADIGM) study

“…The Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging (PARADIGM) study is a dynamic multinational observational registry that prospectively collected clinical, procedural, and follow-up data on patients who underwent clinically indicated serial CCTAs at an inter-scan interval of > _2 years between 2003 and 2015. 14 Clinical and laboratory results were collected within 1 month from both baseline and follow-up CCTA scans and clinical outcomes were followed. Hyperlipidaemia was defined using clinical guidelines at the time of enrolment of each patient.…”

Longitudinal quantitative assessment of coronary plaque progression related to body mass index using serial coronary computed tomography angiography

“…The overall study design of the Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography IMaging (PARADIGM) registry has been previously described. 8 Briefly, the PARADIGM is a prospective, open-label, international, multicentre dynamic observational registry designed to evaluate associations between changes in serial CCTA imaging findings and clinical presentation. Between 2003 and 2015, a total of 2252 consecutive subjects underwent CCTA at 13 centres in seven countries (Supplementary data online, Table S1).…”

Prognostic Value and Therapeutic Perspectives of Coronary CT Angiography: A Literature Review

“…Although currently it is not possible to recommend serial scans to monitor the therapeutic efficacy of a medical interventions, the plaque modulation, as a part of risk modification, is a feasible strategy. Direct visualization of the natural course of atherosclerosis, as well as identification of the clinical determinants of plaque progression or regression, holds the potential to shift the paradigm of CAD monitoring among low- to moderate-risk patients with suspected CAD, with aims of offering earlier therapeutic strategies [ 127 ]. It is reasonable to accept that a substantial reduction in plaque vulnerability by therapeutic intervention should contribute into plaque stability and in turn decrease cardiovascular event rates.…”